Aktienanalyse zu Adial Pharmaceuticals Inc (ADIL)ADILAdial Pharmaceuticals Inc

Adial Pharmaceuticals, Inc. is a biopharmaceutical company. Its lead program is AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis. AT177 is a fully synthetic, patented, oral AhR agonist designed to restore mucosal immune homeostasis at the site of disease with minimal systemic exposure. AT177's active ingredient is a prodrug of indirubin, a potent AhR agonist within indigo naturalis, a botanical extract with clinical efficacy in ulcerative colitis. AT177's colon-targeted formulation delivers therapeutic AhR engagement directly to the colonic mucosa with exquisite gut restriction, minimizing the systemic AhR exposure associated with adverse effects. Its historical investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder in heavy drinking patients. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Adial Pharmaceuticals appears to be a good buy right now, primarily due to its recent acquisition of Azora Therapeutics, which has the potential to enhance its product pipeline significantly. The current price is $5.05, and the RSI is at 77.55, indicating strong momentum. Additionally, the forward P/E ratio is 0, suggesting that the stock is currently undervalued relative to its future earnings potential. However, the company reported a significant net loss of $51,989,000 in Q2 2026, which poses a risk to its financial stability.

2 analysts cover ADIL: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 1.50.